Agalsidase Beta (Fabrazyme®)

Fabrazyme (agalsidase beta) is covered for treatment of Fabry disease for up to 12 months at a dosing limit of 1 mg/kg IV no more frequently than every 2 weeks for the FDA‑approved indication. Coverage requires documented deficient α‑galactosidase A activity (leukocytes or fibroblasts) or a pathogenic α‑galactosidase A gene mutation and prescription by or in consultation with a geneticist, endocrinologist, metabolic disorder subspecialist, or lysosomal storage disorder specialist; requests missing these criteria are not eligible.

"Fabrazyme (agalsidase beta) is indicated for the treatment of individuals with Fabry disease."

Sign up to see full coverage criteria, indications, and limitations.